Soligenix Shares Surge 57% on FDA Orphan Drug Designation for Behçet's Disease Treatment

Soligenix's stock is rising 57% in pre-market trade after the FDA granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treating Behçet's Disease. The company hopes dusquetide will help patients with the chronic autoimmune disease, following clinically meaningful improvements seen in a Phase 2 proof-of-concept study.

Soligenix, Inc. (NASDAQ: SNGX) saw its stock rise by 57% in pre-market trading on July 2, 2025, following the U.S. Food and Drug Administration's (FDA) grant of orphan drug designation to dusquetide, the active ingredient in its SGX945 product, for the treatment of Behçet's Disease. The designation provides Soligenix with seven years of market exclusivity upon potential FDA approval and positions the company to access various financial and regulatory benefits.

Behçet's Disease is a rare inflammatory disorder affecting approximately 18,000 people in the U.S. and up to 1 million worldwide. The condition causes painful mouth sores in about 95% of patients, along with skin rashes, genital sores, leg ulcers, and eye inflammation. The orphan drug designation follows Soligenix’s Phase 2a pilot study involving eight patients with Behçet’s Disease, which showed a 40% improvement in oral ulcers after four weeks of treatment compared to placebo data [1].

The designation provides Soligenix with substantial regulatory advantages and market exclusivity, boosting its position in the Behçet's Disease treatment market. This development marks a significant milestone for the company, as the results were comparable to the existing treatment, apremilast [2]. The FDA previously granted Fast-Track designation to dusquetide for treating oral lesions of Behçet’s Disease, further highlighting its potential in addressing an unmet medical need.

Soligenix's Phase 2a study demonstrated biological efficacy and safety, specifically showing clinically meaningful improvements in patients with oral aphthous ulcers due to Behçet's Disease. Dusquetide is an innate defense regulator that modulates the body's reaction to injury and infection, offering a potential alternative to currently approved treatments like apremilast, which can cause side effects such as diarrhea and nausea [3].

The FDA's decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix, adding significantly to the existing intellectual property estate surrounding this novel technology. The company now benefits from enhanced FDA interaction opportunities and a potentially streamlined approval process specifically designed for orphan drugs treating serious conditions with unmet needs.

References:
1. [1] https://www.investing.com/news/company-news/fda-grants-soligenix-orphan-drug-designation-for-behcets-disease-93CH-4197504
2. [2] https://www.stocktitan.net/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-the-treatment-of-1ha7eiwia524.html
3. [3] https://www.marketscreener.com/news/fda-grants-soligenix-orphan-drug-designation-for-the-treatment-of-behcet-s-disease-after-reviewing-r-ce7c51dfd088f326